Cargando…
Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
Lumateperone is indicated for the treatment of schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate (Calabrese et al., 2021). It is currently under evaluation fo...
Autores principales: | Dutheil, Sophie, Watson, Luke S., Davis, Robert E., Snyder, Gretchen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899083/ https://www.ncbi.nlm.nih.gov/pubmed/36549907 http://dx.doi.org/10.1523/JNEUROSCI.0984-22.2022 |
Ejemplares similares
-
The role of lumateperone in the treatment of schizophrenia
por: Syed, Alveena Batool, et al.
Publicado: (2021) -
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial
por: Correll, Christoph U., et al.
Publicado: (2020) -
Illuminating Hope for Mental Health: A Drug Review on Lumateperone
por: Tarzian, Martin, et al.
Publicado: (2023) -
New synthesis of a late-stage tetracyclic key intermediate of lumateperone
por: Milen, Mátyás, et al.
Publicado: (2022) -
Management of subjects with Intermittent Explosive Disorder and Autism Spectrum Disorder with Lumateperone
por: Mehdiratta, N., et al.
Publicado: (2023)